title: Nevirapine-based therapy after suppression: can we switch?
authors.affiliation: Pediatrics, Stony Brook University, Stony Brook, NY, USA. Sharon.nachman@stonybrook.edu
authors.forename: Sharon
authors.initials: S
authors.lastname: Nachman
authors.forename: James
authors.initials: J
authors.lastname: McIntyre
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir / Q000627:therapeutic use*; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D061466:Lopinavir; D019829:Nevirapine; D019438:Ritonavir